{
  "docId": "019de073-dba4-758b-bcbe-08ad83e87d71",
  "docSlug": "afc13b14322819221680611098a4aee7",
  "documentTitle": "Third Harmonic Bio | Investor Presentation Deck | 20 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 20,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines a randomized, placebo-controlled trial structure with specific weeks and days for allergen challenges and measurements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-dba4-758b-bcbe-08ad83e87d71/18",
  "deckHref": "/decks/019de073-dba4-758b-bcbe-08ad83e87d71",
  "deckJsonHref": "/decks/019de073-dba4-758b-bcbe-08ad83e87d71.json",
  "deckAnchorHref": "/decks/019de073-dba4-758b-bcbe-08ad83e87d71#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.25,
        "x": 0.72,
        "y": 0.23
      },
      "kind": "callout",
      "text": "Established clinical POC model for asthma\nElevated mast cell gene signature in this model consistent with severe asthma\nDose ranging design to provide early assessment of therapeutic index\nPlanned study initiation in 1H:23",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d81bd54-9fc2-4be5-9326-266b76780bf2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.65,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Trial timeline showing screening, baseline, randomization, and dosing weeks 2 through 12.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43eda8ef-5999-47de-ab94-28837693ae63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.03,
        "y": 0.7
      },
      "kind": "list",
      "text": "Study Design: Parallel, Blinded, PBO controlled, 2-3 THB001 doses + PBO (1:1:1): N=~10-15/arm\nPatient Population: mild, stable allergic asthmatic subjects, not on regular anti-inflammatory treatment\nPrimary Endpoint: change from baseline in FEV during LAR\nMeasurements/Biomarkers: FEV1, Airway Hyper Responsiveness (AHR), serum tryptase, sputum used as matrix for biomarkers of immune function (cytokines, eos, etc), Skin Prick Test (SPT)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93dce387-2b24-4870-8f10-468a6e5f7e00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.83,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1Murphy et al. ACS 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bb63417-1040-4069-9264-bd87b59c029d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 1b Inducible Allergic Asthma POC Trial Concept Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b9e3e8a-7804-4b5d-8a0b-07cb5bfb69a7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "abedeb5d-4da7-4dbb-881f-b5daf22668ec",
      "evidence": "list/bullet: Patient Population: mild, stable allergic asthmatic subjects, not on regular anti-inflammatory treatment",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "dc9b7f64-d6e2-4ce6-8ce2-1848de715318",
      "evidence": "The timeline visualization of trial phases and dosing intervals.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}